Study of Molecular and Epigenetic Factors Influencing Immunotherapy Response in Advanced or Recurrent Endometrial Cancer

What this Trial Is About

Researchers are investigating how molecular and epigenetic factors influence the success of immunotherapy in advanced or recurrent endometrial cancer. The study focuses on understanding why responses to immune checkpoint inhibitors vary among patients, especially considering mismatch repair status, to find better ways to predict who may benefit from these treatments. This research aims to identify biomarkers that can guide personalized immunotherapy in endometrial cancer. Participants will be part of a prospective exploratory cohort where fresh tumor samples, along with preserved tissue, will be collected before starting immunotherapy. These samples will be used to create patient-specific three-dimensional tumoroids on a microfluidic organ-on-chip platform to explore the biological mechanisms behind treatment response. The study involves advanced analyses including genomic, epigenomic, transcriptomic, proteomic, and lipidomic assessments. During the study, participants will provide tumor tissue samples prior to immunotherapy initiation, and researchers will assess outcomes such as progression-free survival and overall survival over two years. These detailed molecular and laboratory evaluations aim to link patient tumor characteristics with treatment results. The study will continue until April 2029, with no mention of additional follow-up periods beyond the molecular analyses and outcome tracking.

DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER